Halaven (eribulin), from Eisai, is an active agent against liposarcoma according to tumour subtype analyses of a Phase III trial...
The German Institute for Quality and Efficiency in Health Care (IQWiG) has published a report which suggests that on formal...
The FDA has approved Halaven (eribulin mesylate) Injection (0.5 mg per mL), from Eisai, for the treatment of patients with...
Eisai Co., Ltd has announced that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the...
The European Commission has approved Halaven (eribulin), from Eisai, for the treatment of adult patients with unresectable liposarcomas who have...
Phase III data showed that Halaven (eribulin), from Eisai, offers a significant overall survival benefit in people with advanced leiomyosarcoma...
Full results from the phase III study 309 have been published for the first time in The Lancet, and show...
HALAVEN is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. HALAVEN is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).
Janssen Research & Development has submitted a New Drug Application (NDA) for Yondelis (trabectedin) to the FDA for the treatment...